Yes, empagliflozin is an SGLT2 inhibitor
Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that works by blocking glucose reabsorption in the kidney's proximal tubule, leading to increased urinary glucose excretion. 1
Mechanism of Action
Empagliflozin specifically inhibits SGLT2, the predominant transporter responsible for reabsorbing filtered glucose from the glomerular filtrate back into circulation. By blocking this transporter, empagliflozin:
- Reduces renal glucose reabsorption
- Lowers the renal threshold for glucose
- Increases urinary glucose excretion (approximately 64-78 grams per day depending on dose) 1
Selectivity Profile
Among SGLT2 inhibitors, empagliflozin is one of the most selective for SGLT2 receptors 2. It demonstrates:
- High specificity for SGLT2 over SGLT1 2
- The highest SGLT2 specificity among all clinically used or currently tested SGLT2 inhibitors 3
- Potent and selective inhibition of SGLT2 4, 5
Clinical Classification
Empagliflozin is consistently classified alongside other SGLT2 inhibitors (canagliflozin, dapagliflozin, ertugliflozin) in major clinical guidelines 6, 7, 8, 7. It shares the class characteristics of:
- Insulin-independent glucose lowering
- Cardiovascular and renal protective effects
- Similar safety profile (genital mycotic infections, volume depletion risk)
- Contraindication in severe renal impairment and dialysis 6, 8
The FDA-approved indications confirm its classification as an SGLT2 inhibitor for improving glycemic control in type 2 diabetes and reducing cardiovascular death risk in patients with established cardiovascular disease 6, 8, 7.